Human insulin and its analog injection-induced localized lipoatrophy: 6 case reports and systemic review
10.3760/cma.j.issn.1674-635X.2017.04.005
- VernacularTitle:人胰岛素及类似物注射致局部脂肪萎缩6例报告及文献回顾
- Author:
Shuo ZHANG
;
Naishi LI
;
Li LI
;
Jianqing GU
;
Jiangfeng MAO
;
Lingling XU
;
Yan JIANG
;
Fan PING
;
Shi CHEN
;
Weigang ZHAO
- Keywords:
Insulin-induced localized lipoatrophy;
Insulin allergy;
Insulin-autoimmune antibody
- From:
Chinese Journal of Clinical Nutrition
2017;25(4):226-232
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate clinical and pathological characteristics of insulin-induced localized lipoatrophy and treatment.Methods We retrospectively analyzed clinical manifestation, skin biopsy pathology, treatment regimen and follow-up of 6 diabetic patients with insulin-induced localized lipoatrophy in Peking Union Medical College Hospital from January, 2010 to March, 2016, with systemic review of related literatures.Results Among 6 cases with insulin-induced localized lipoatrophy, 5 patients were with insulin allergy.5 patients were with positive insulin-autoimmune antibody, which was similar to the ratio reported in the systematic review (18 out of 19).Insulin-induced lipoatrophy could be caused by various types of preparations of insulin and insulin analogs.Subcutaneous biopsy, performed on the atrophied area, revealed the decrease of the number and volume of adipocytes and tissue fibrosis, probably accompanied with lymphocytes, eosinophils or mast cells infiltration.Lipoatrophy could sometimes be relieved by changing injection sites, types of insulin preparations or drug-delivery way, sometimes by application of systemic/local glucocorticoid or local cromolyn sodium.Conclusions Insulin-induced localized lipoatrophy is a rare adverse reaction of insulin preparations.It might be related to immune response of local tissue and heterogeneous pathological manifestations.The lipoatrophy might be improved by changing injection sites, changing the type of insulin preparations or drug-delivery way, and with possibility to carry out targeted immunosuppressive therapy according to the biopsy pathology in the future.
